Kyowa Kirin KHK4951 Eye Drops Report Phase 2 nAMD Data as Primary Endpoint Is Missed
Kyowa Kirin KHK4951 eye drops missed their Phase 2 primary endpoint in neovascular age-related macular degeneration, though most patients maintained vision through Week 52 with no new safety signals in Study 4951-002.
